TMED - Trimedyne, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
5.0000
0.0000 (0.00%)
As of 3:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.0000
Open5.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range5.0000 - 5.0000
52 Week Range3.6900 - 11.0000
Volume530
Avg. Volume71
Market Cap616,525
Beta (3Y Monthly)-2.19
PE Ratio (TTM)2.62
EPS (TTM)1.9080
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 months ago

    Trimedyne Mourns the Death of Marvin P. Loeb

    Irvine, CA, March 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- TRIMEDYNE, INC. (OTC PINK “TMED”) today announced with sorrow the death of Marvin P. Loeb, Sc. D.  Dr. Loeb was the Founder and a director of Trimedyne since 1980 and its Chairman of the Board from March 1981 to July 15, 2018. Marvin P. Loeb died a few days after a recent surgery on March 24, 2019 in Lake Forest, CA.

  • GlobeNewswire4 months ago

    Trimedyne Reports Its Financial Results For The Quarter Ending on December 31, 2018

    IRVINE, CA, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on December 31, 2018. For the Quarter Ended December 31, 2018, Trimedyne had revenues of $1,188,000, a decrease of 23% from revenues of $1,534,000 for the prior year quarter.  As a result of this decrease, we had a net loss for the current quarter of $31,000 or $0.25 per share, as compared to net income of $86,000 or $0.70 per share for the prior year quarter. Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited.  However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the period and dates shown in the financial statements attached herein.

  • GlobeNewswire6 months ago

    Trimedyne Reports Its Financial Results for Its Fiscal Year Ending on September 30, 2018

    Irvine, California, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- TRIMEDYNE, INC. (OTCBB “TMED”) today reported its financial results for its Fiscal Year ending on September 30, 2018. For the Fiscal Year Ended September 30, 2018, Trimedyne had revenues of $5,567,000, an increase of 18.6% from revenues of $4,695,000 for the prior year.  We had net income for the current year of $234,000 or $1.91 per share, as compared to a net loss of $44,000 or $0.36 per share for the prior year, adjusted for a 150 to one reverse stock split in November, 2016. This $278,000 increase compared to the prior fiscal year is a considerable improvement, which was primarily the result of the increase in sales stated above.